Skip to main content
SpringerLink
Log in

Octreotide as first-line treatment for women with metastatic breast cancer

  • Brief Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 μg subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dhodapkar MV, Ingle JN, Cha SS, Mailliard JA, Wieand HS: Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen. An analysis of patients entered on four prospective clinical trials. Cancer 77:683–690, 1995

    Google Scholar 

  2. Furlanetto RW, DiCarlo JN: Somatomedin-C receptors and growth effects in human breast cells maintained in longterm tissue culture. Cancer Res 44:2122–2128, 1984

    Google Scholar 

  3. Roberts Jr CT, Brown AL, Graham DE, Seelig S, Berry S, Gabbay KH, Rechler MM: Growth hormone regulates the abundance of insulin-like growth factor I RNA in adult rat liver. J Biol Chem 261:10025–10028, 1986

    Google Scholar 

  4. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J: SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133–1140, 1982

    Google Scholar 

  5. Setyono-Han B, Henkelman MS, Foekens JA, Klijn JGM: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47:1566–1570, 1987

    Google Scholar 

  6. Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gesme DH, Windschitl HE, Pfeifle DM, Etzell PS, Gerstner JG, Long HJ, Foley JF, Loprinzi CL, Dalton RJ: A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. Cancer 68:34–39, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic and Mayo Foundation, 55905, Rochester, MN, USA

    James N. Ingle MD & Vera J. Suman

  2. Ochsner Community Clinical Oncology Program (CCOP), 70121, New Orleans, LA, USA

    Carl G. Kardinal

  3. Duluth CCOP, 55805, Duluth, MN, USA

    James E. Krook

  4. Carle Cancer Center CCOP, 61801, Urbana, IL, USA

    Alan K. Hatfield

Authors
  1. James N. Ingle MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carl G. Kardinal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vera J. Suman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James E. Krook
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alan K. Hatfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ingle, J.N., Kardinal, C.G., Suman, V.J. et al. Octreotide as first-line treatment for women with metastatic breast cancer. Invest New Drugs 14, 235–237 (1996). https://doi.org/10.1007/BF00210797

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00210797

Key words

Search

Navigation